Haemonetics (FRA:HAZ) Total Stockholders Equity : €865 Mil (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Haemonetics Total Stockholders Equity?

Haemonetics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €865 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Haemonetics's Book Value per Share for the quarter that ended in Dec. 2023 was €17.03. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Haemonetics's Debt-to-Equity for the quarter that ended in Dec. 2023 was 0.92.

Haemonetics Total Stockholders Equity Historical Data

The historical data trend for Haemonetics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Haemonetics Total Stockholders Equity Chart

Haemonetics Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Total Stockholders Equity

Get a 7-Day Free Trial

591.06

531.33

614.60

680.48

764.01

Haemonetics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Stockholders Equity	Get a 7-Day Free Trial															732.52	764.01	798.04	837.36	865.02

Haemonetics (FRA:HAZ) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Haemonetics's Book Value per Share for the quarter that ended in Dec. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(865.024	-	0)	/	50.785
	=	17.03

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Haemonetics's Debt-to-Equity for the quarter that ended in Dec. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(12.596	+	785.731)	/	865.024
	=	0.92

Haemonetics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Haemonetics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Haemonetics (FRA:HAZ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Haemonetics Corp (FRA:HAZ) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

HAE:USA HAZ:Germany

Address

125 Summer Street, Boston, MA, USA, 02110

Website

https://www.haemonetics.com

Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.

Haemonetics (FRA:HAZ) Headlines

No Headlines